Journal of advanced research · 2025
Peroxisomal dysfunction in cardiac adipose tissue is involved in obesity-associated cardiac hypertrophy.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Song Gahee, Jung Se Jin, Jiao Wenjun, Park Woo Yong, Jo Yunju, Park Ja Yeon, Choe Seong-Kyu, Ha In Jin, Kim Peter K, Ryu Dongryeol, Son Kuk Hui, Kwak Hyun Jeong, Um Jae-Young
Аннотация
INTRODUCTION: Cardiac adipose tissue, which directly interfaces with the myocardium and vasculature, has a pivotal role in obesity-related cardiovascular pathology through its metabolic activity. This tissue contributes to cardiac remodeling through its regulation of lipid metabolism. Among the key organelles involved, peroxisomes have a central role in lipid metabolism, yet their contribution to obesity-induced cardiac dysfunction remains poorly understood.
OBJECTIVES: This study investigated whether peroxisomal dysfunction in cardiac adipose tissue drives obesity-associated cardiac hypertrophy.
METHODS: Using a high-fat diet (HFD)-induced obese rat model, we evaluated changes in cardiac adipose tissues, focusing on their browning capacity and metabolic functions. To investigate mechanistic effects, H9C2 cardiomyocytes were exposed either to fatty acids extracted from cardiac adipose tissues or conditioned medium derived from adipocytes treated with mitochondrial and peroxisomal inhibitors (Mdivi-1 or 10,12-tricosadiynoic acid).
RESULTS: HFD-fed obese rats exhibited significant expansion of cardiac adipose tissues and cardiac hypertrophy, driven by impaired lipid metabolism and loss of browning capacity in cardiac fat associated with peroxisomal dysfunction. Treatment of H9C2 cardiomyocytes with conditioned medium from adipocytes with peroxisomal dysfunction induced collagen accumulation, increased expression of pro-inflammatory cytokines, and cellular hypertrophy, which recapitulates key pathological features observed in vivo.
CONCLUSION: Our findings demonstrate that peroxisomal dysfunction in cardiac adipose tissue drives lipid metabolic reprogramming and contributes to obesity-related cardiac hypertrophy. Targeting peroxisomal function in cardiac fat could be a novel therapeutic approach to mitigate obesity-induced cardiovascular remodeling.
OBJECTIVES: This study investigated whether peroxisomal dysfunction in cardiac adipose tissue drives obesity-associated cardiac hypertrophy.
METHODS: Using a high-fat diet (HFD)-induced obese rat model, we evaluated changes in cardiac adipose tissues, focusing on their browning capacity and metabolic functions. To investigate mechanistic effects, H9C2 cardiomyocytes were exposed either to fatty acids extracted from cardiac adipose tissues or conditioned medium derived from adipocytes treated with mitochondrial and peroxisomal inhibitors (Mdivi-1 or 10,12-tricosadiynoic acid).
RESULTS: HFD-fed obese rats exhibited significant expansion of cardiac adipose tissues and cardiac hypertrophy, driven by impaired lipid metabolism and loss of browning capacity in cardiac fat associated with peroxisomal dysfunction. Treatment of H9C2 cardiomyocytes with conditioned medium from adipocytes with peroxisomal dysfunction induced collagen accumulation, increased expression of pro-inflammatory cytokines, and cellular hypertrophy, which recapitulates key pathological features observed in vivo.
CONCLUSION: Our findings demonstrate that peroxisomal dysfunction in cardiac adipose tissue drives lipid metabolic reprogramming and contributes to obesity-related cardiac hypertrophy. Targeting peroxisomal function in cardiac fat could be a novel therapeutic approach to mitigate obesity-induced cardiovascular remodeling.